Conducting omega-3 clinical trials with cardiovascular outcomes: Proceedings of a workshop held at ISSFAL 2014

Harry B. Rice, Aldo Bernasconi, Kevin C. Maki, William Harris, Clemens von Schacky, Philip C. Calder

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

In contrast to earlier long-chain (LC) omega-3 (i.e. EPA and DHA) investigations, some recent studies have not demonstrated significant effects of EPA and DHA on cardiovascular disease (CVD) outcomes. The neutral findings may have been due to experimental design issues, such as: maintenance on aggressive cardiovascular drug treatment overshadowing the benefits of LC omega-3s, high background LC omega-3 intake, too few subjects in the study, treatment duration too short, insufficient LC omega-3 dosage, increase in omega-6 fatty acid intake during the study, failure to assess the LC omega-3 status of the subjects prior to and during treatment and lack of clarity concerning which mechanisms were expected to produce benefits. At the 11th ISSFAL Congress, a workshop was held on conducting LC omega-3 clinical trials with cardiovascular outcomes, with the goal of gaining a better understanding concerning aspects of experimental design that should be considered when planning clinical studies related to EPA and DHA and potential cardiovascular benefits.

Original languageEnglish (US)
Pages (from-to)30-42
Number of pages13
JournalProstaglandins Leukotrienes and Essential Fatty Acids
Volume107
DOIs
StatePublished - Apr 1 2016
Externally publishedYes

Fingerprint

Design of experiments
Research Design
Omega-6 Fatty Acids
Clinical Trials
Drug therapy
Education
Cardiovascular Agents
Cardiovascular Diseases
Maintenance
Planning
Clinical Studies

Keywords

  • Cardiovascular disease
  • Design
  • Docosahexaenic
  • Eicosapentaenoic
  • Omega-3

ASJC Scopus subject areas

  • Cell Biology
  • Clinical Biochemistry

Cite this

Conducting omega-3 clinical trials with cardiovascular outcomes : Proceedings of a workshop held at ISSFAL 2014. / Rice, Harry B.; Bernasconi, Aldo; Maki, Kevin C.; Harris, William; von Schacky, Clemens; Calder, Philip C.

In: Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 107, 01.04.2016, p. 30-42.

Research output: Contribution to journalArticle

Rice, Harry B. ; Bernasconi, Aldo ; Maki, Kevin C. ; Harris, William ; von Schacky, Clemens ; Calder, Philip C. / Conducting omega-3 clinical trials with cardiovascular outcomes : Proceedings of a workshop held at ISSFAL 2014. In: Prostaglandins Leukotrienes and Essential Fatty Acids. 2016 ; Vol. 107. pp. 30-42.
@article{2405e4443e16477d8e752d729ccfb0bb,
title = "Conducting omega-3 clinical trials with cardiovascular outcomes: Proceedings of a workshop held at ISSFAL 2014",
abstract = "In contrast to earlier long-chain (LC) omega-3 (i.e. EPA and DHA) investigations, some recent studies have not demonstrated significant effects of EPA and DHA on cardiovascular disease (CVD) outcomes. The neutral findings may have been due to experimental design issues, such as: maintenance on aggressive cardiovascular drug treatment overshadowing the benefits of LC omega-3s, high background LC omega-3 intake, too few subjects in the study, treatment duration too short, insufficient LC omega-3 dosage, increase in omega-6 fatty acid intake during the study, failure to assess the LC omega-3 status of the subjects prior to and during treatment and lack of clarity concerning which mechanisms were expected to produce benefits. At the 11th ISSFAL Congress, a workshop was held on conducting LC omega-3 clinical trials with cardiovascular outcomes, with the goal of gaining a better understanding concerning aspects of experimental design that should be considered when planning clinical studies related to EPA and DHA and potential cardiovascular benefits.",
keywords = "Cardiovascular disease, Design, Docosahexaenic, Eicosapentaenoic, Omega-3",
author = "Rice, {Harry B.} and Aldo Bernasconi and Maki, {Kevin C.} and William Harris and {von Schacky}, Clemens and Calder, {Philip C.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.plefa.2016.01.003",
language = "English (US)",
volume = "107",
pages = "30--42",
journal = "Prostaglandins Leukotrienes and Essential Fatty Acids",
issn = "0952-3278",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Conducting omega-3 clinical trials with cardiovascular outcomes

T2 - Proceedings of a workshop held at ISSFAL 2014

AU - Rice, Harry B.

AU - Bernasconi, Aldo

AU - Maki, Kevin C.

AU - Harris, William

AU - von Schacky, Clemens

AU - Calder, Philip C.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - In contrast to earlier long-chain (LC) omega-3 (i.e. EPA and DHA) investigations, some recent studies have not demonstrated significant effects of EPA and DHA on cardiovascular disease (CVD) outcomes. The neutral findings may have been due to experimental design issues, such as: maintenance on aggressive cardiovascular drug treatment overshadowing the benefits of LC omega-3s, high background LC omega-3 intake, too few subjects in the study, treatment duration too short, insufficient LC omega-3 dosage, increase in omega-6 fatty acid intake during the study, failure to assess the LC omega-3 status of the subjects prior to and during treatment and lack of clarity concerning which mechanisms were expected to produce benefits. At the 11th ISSFAL Congress, a workshop was held on conducting LC omega-3 clinical trials with cardiovascular outcomes, with the goal of gaining a better understanding concerning aspects of experimental design that should be considered when planning clinical studies related to EPA and DHA and potential cardiovascular benefits.

AB - In contrast to earlier long-chain (LC) omega-3 (i.e. EPA and DHA) investigations, some recent studies have not demonstrated significant effects of EPA and DHA on cardiovascular disease (CVD) outcomes. The neutral findings may have been due to experimental design issues, such as: maintenance on aggressive cardiovascular drug treatment overshadowing the benefits of LC omega-3s, high background LC omega-3 intake, too few subjects in the study, treatment duration too short, insufficient LC omega-3 dosage, increase in omega-6 fatty acid intake during the study, failure to assess the LC omega-3 status of the subjects prior to and during treatment and lack of clarity concerning which mechanisms were expected to produce benefits. At the 11th ISSFAL Congress, a workshop was held on conducting LC omega-3 clinical trials with cardiovascular outcomes, with the goal of gaining a better understanding concerning aspects of experimental design that should be considered when planning clinical studies related to EPA and DHA and potential cardiovascular benefits.

KW - Cardiovascular disease

KW - Design

KW - Docosahexaenic

KW - Eicosapentaenoic

KW - Omega-3

UR - http://www.scopus.com/inward/record.url?scp=84962052424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962052424&partnerID=8YFLogxK

U2 - 10.1016/j.plefa.2016.01.003

DO - 10.1016/j.plefa.2016.01.003

M3 - Article

C2 - 26858145

AN - SCOPUS:84962052424

VL - 107

SP - 30

EP - 42

JO - Prostaglandins Leukotrienes and Essential Fatty Acids

JF - Prostaglandins Leukotrienes and Essential Fatty Acids

SN - 0952-3278

ER -